Slide 1: Investor Presentation
For personal use only Investor Presentation 20 March 2013
Slide 2: Disclaimer
For personal use only DISCLAIMER The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s
Slide 3: Managing for Growth
For personal use only MANAGING FOR GROWTH • Who is Clover • What Wh t h happened d iin 1HFY2013 • Historical performance • Clover’s competitive strengths • Clover’s strategy – Focus on the core business & new product pipeline – Opportunities for medical food applications – preterm i f t foods infant
Slide 4: Strategic Vision
For personal use only STRATEGIC VISION Clover Corporation seeks to: • Identify, develop and commercialise speciality functional and nutritional ingredients in the growing nutraceutical & medical markets • Develop and commercialise leading edge proprietary and patented delivery technologies including
Slide 5: Company Description
For personal use only COMPANY DESCRIPTION • Focus on two business units: – Clover Corporation focuses on innovation, obtaining the optimal return from proprietary technology and developing new business opportunities – Nu-Mega Ingredients (100% owned subsidiary) commercialises proprietary ingredient
Slide 6: Overview of Nu-Mega Operations
OVERVIEW OF NU-MEGA OPERATIONS For personal use only Maximize the use of proprietary bioactive delivery technology Algal & Tuna oil Other bioactives other oils Purchase from various sources Refine Medical & infant Emulsion formulations Tuna oil Infant formula, functional Microencapsulated foods & Po
Slide 7: Key Company Developments
KEY COMPANY DEVELOPMENTS For personal use only 2012- • Building business plan for medical related 2007-2012 opportunities arising from core • Nu-Mega Ingredients 100% competencies subsidiary of Clover Corp. • Enters Phase 3 preterm • 2008 - New Innovation & infant formula trial – Sales facility in B
Slide 8: Trading Update & Outlook for FY2013
For personal use only TRADING UPDATE & OUTLOOK FOR FY2013 • 12.5% increase in sales revenue in the first half FY2013 (pcp). – Increased sales in infant formula applications. – Featuring Oceania and Asia. • Re-signed 5 year supply contract with major multi-national infant formula manufacturer. • Posi
Slide 9: Sales Revenue +12.5% in the First Half FY2013
SALES REVENUE +12.5% IN THE FIRST HALF FY2013 For personal use only (as reported) million ($) 20 15 10 5 0 1HFP11 1HFY12 1HFY13 Sales Revenue 9
Slide 10: Clover Half Year FY2013 Results
CLOVER HHalf lf Y Year FY2013 RESULTS For personal use only Period ended 31 January 2013 AUD $ million 1H FY2013 1H FY2012 Underlying to 31 January 2013 to 31 January 2012 1HFY2012 (as reported) (Unaudited, eliminating FFI cost) Revenue ($m) $20.2 $17.9 $17.9 Profit before tax ($m) $3.8 $2.8 $3.8 De
Slide 11: Historical Performance
HISTORICAL PERFORMANCE For personal use only First Half Financial Year (as reported) Period end Period end Period end Period end Period end Period end AUD $ million 31/1/13 31/1/12 * 31/12/10 31/12/09 31/12/08 31/12/07 Sales Revenue $20.2 $17.9 $14.0 $16.4 $9.1 $9.4 Cash total $9.7 $7.1 $9.2 $8.1 $9
Slide 12: Historical Financial Performance
HISTORICAL FINANCIAL For personal use only PERFORMANCE FP2011 AUD million FY2012 FY2010 # FY2009 FY2008 FY2007 (13 months) Shares on issue (m) 165.2 165.2 165.2 165.2 165.2 165.2 Total contributed equity $29.9 $28.1 $25.6 $28.3 $27.0 $23.7 ($m) Cash total ($m) $9.7 $7.4 $12.2 $9.2 $10.8 $11.0 Sales
Slide 13: Continued Focus on Growth Markets & Value Added Products
CONTINUED FOCUS ON GROWTH MARKETS & VALUE ADDED For personal use only PRODUCTS FY2012 Geographic • Sales revenue increased with the strongest performance in Oceania. Oceania 26% • Focus has been on infant formula & Asia 64% children’s food applications. Europe 6% • The expansion of sales in value ad
Slide 14: Delivery Systems Based on a Variety of Nutritional Bioactives
DELIVERY SYSTEMS BASED ON A VARIETY OF NUTRITIONAL BIOACTIVES For personal use only • Product portfolio includes refined tuna Sales Revenue based on oil and encapsulated powders containing Diversified Bioactives in FY2012 marine oil oil, algal oils, oils other specialty oils and important micronutri
Slide 15: Competitive Strengths – A Culture of Commercial Innovation
COMPETITIVE STRENGTHS – A CULTURE OF COMMERCIAL INNOVATION For personal use only • Clover’s core strengths; – Focus on value added markets – Proprietary & patented technology – C Commercial i l focus f on innovation i ti program – High quality differentiated products – Excellent reputation with clie
Slide 16: Research & Development Expenditure
RESEARCH & DEVELOPMENT EXPENDITURE For personal use only (EXPENSED IN YEAR OF ACTIVITY) million ($) 2.00 * 1.50 1.00 0.50 0.00 FY07 FY08 FY09 FY10 FP11 FY12 R&D Expenditure * FP11 represents 13 months 16
Slide 17: Focus on the Growth of the Core Business
FOCUS ON THE GROWTH OF THE CORE BUSINESS For personal use only Core business & new product development: • Continued focus on the infant formula and children’s food market. – Specialist delivery systems. – Targeted multiple bioactive delivery systems. – Improved bioactive protection. • Developing new
Slide 18: The Opportunities for Medical Applications
THE OPPORTUNITIES FOR MEDICAL APPLICATIONS For personal use only New Medical & Pharmaceutical applications: • Clover has supported pp strategic g clinical studies for many y years y and this assists in identifying new commercial opportunities. • Medical issues that affect preterm infants include: –
Slide 19: Preterm Infant Formulation
PRETERM INFANT FORMULATION For personal use only • Clover developed a specialty formulation for hospital use: – Licence agreements signed & patent applications filed. – Proprietary formulation & delivery system being manufactured for trials. – Successful clinical testing of the formulation and deliv
Slide 20: Thank You
For personal use only THANK YOU Questions? 20